On the other hand, the National Comprehensive Cancer Network (NCCN) guidelines suggest that SG can be used in the second-line setting for unresectable locally advanced or metastatic HR+, HER2-negative breast cancer if the patient is not a candidate for T-DXd and can be considered beyond second-line treatment [63] (Figure 1). This evidence concerns the gene ERBB2 and breast carcinoma.